Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to Hold at Wall Street Zen

Kyverna Therapeutics (NASDAQ:KYTX) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Other research analysts have also issued reports about the company. Morgan Stanley set a $33.00 target price on Kyverna Therapeutics in a report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Monday, December 29th. Finally, Wells Fargo & Company boosted their price objective on Kyverna Therapeutics from $31.00 to $33.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $28.67.

Kyverna Therapeutics Stock Up 1.1%

Shares of KYTX stock opened at $8.21 on Friday. The firm has a 50 day moving average of $8.43 and a two-hundred day moving average of $6.92. The stock has a market capitalization of $359.60 million, a PE ratio of -2.20 and a beta of 3.45. Kyverna Therapeutics has a 52 week low of $1.78 and a 52 week high of $13.67.

Insider Transactions at Kyverna Therapeutics

In other Kyverna Therapeutics news, Director Beth C. Seidenberg bought 133,333 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The stock was purchased at an average price of $7.50 per share, for a total transaction of $999,997.50. Following the completion of the purchase, the director directly owned 869,317 shares in the company, valued at $6,519,877.50. This trade represents a 18.12% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Biopartners Opportuni Westlake purchased 133,333 shares of the stock in a transaction that occurred on Thursday, December 18th. The stock was acquired at an average cost of $7.50 per share, with a total value of $999,997.50. Following the completion of the acquisition, the insider directly owned 869,317 shares of the company’s stock, valued at $6,519,877.50. This represents a 18.12% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 22.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of KYTX. Bank of America Corp DE lifted its position in Kyverna Therapeutics by 41.6% in the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock valued at $81,000 after acquiring an additional 6,400 shares during the last quarter. Cubist Systematic Strategies LLC lifted its holdings in shares of Kyverna Therapeutics by 31.1% in the 1st quarter. Cubist Systematic Strategies LLC now owns 68,628 shares of the company’s stock valued at $132,000 after purchasing an additional 16,267 shares during the last quarter. AQR Capital Management LLC acquired a new stake in shares of Kyverna Therapeutics in the 1st quarter valued at about $137,000. Rhumbline Advisers boosted its position in shares of Kyverna Therapeutics by 22.0% in the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after purchasing an additional 5,694 shares during the period. Finally, Ethic Inc. purchased a new position in Kyverna Therapeutics during the 2nd quarter worth approximately $56,000. 18.08% of the stock is owned by hedge funds and other institutional investors.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.